A Phase 4 interventional study of Bosentan and Placebo in Pulmonary Arterial Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 30 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one is the 5th largest by enrollment, is one of 2 that started in 2006, is one of 6 in phase 4, and was the 5th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:
Silvia Ulrich · Sites in Switzerland
Ages 18–80
By country, each count listing its studies:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 8 · Phase 4 6
First in 2002; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 23 across the 18 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
14 studies in Pulmonary Arterial Hypertension by Viatris Inc.: none open now, none under way, none of them phase 3. Of 9 finished, 8 (89%) have results posted.
Among the 14 studies in Pulmonary Arterial Hypertension by Viatris Inc., this one is the only one that started in 2006, is one of 4 in phase 4, and was the 3rd registered.
Viatris Inc.’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 14 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the efficacy and safety of sildenafil when added to patients with PAH who are taking bosentan as all or part of their background therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Bosentan · Other: Placebo
Drug: Bosentan · Drug: Sildenafil Citrate
Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
Change From Baseline in the Total Distance Walked During 6 Minute Walk Time (6MWT) at Week 12
6MWT is the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety.
Time frame: Week 12
Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Class in Participants With PAH at Week 12 LOCF
WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity) to Class IV (can not perform a physical activity without any symptoms, dyspnea at rest). Improvement=reduction in functional class; deterioration = increase in functional class, no change = no change in functional class.
Time frame: Week 12
Clinical Worsening Events
No survival analysis was carried out for the study due to very few events of clinical worsening. Hence, we present a summary of clinical worsening events instead. Events of clinical worsening were categorized as (A). Death, (B). Heart/lung transplantation, (C). Hospitalization due to pulmonary arterial hypertension (PAH), and (D). Clinical deterioration of PAH requiring additional therapy.
Time frame: Week 12
Change From Baseline in Borg Dyspnea Score at Week 12
Borg dyspnea scale is a 10-point scale where following scores stands for severity of dyspnea: 0 (no breathlessness at all); 0.5 (very very slight \[just noticeable\]); 1. (very slight); 2. (slight breathlessness); 3. (moderate); 4 (some what severe); 5 (severe breathlessness); 7 (very severe breathlessness); 9 (very very severe \[almost maximum\]); and 10 (maximum).
Time frame: Week 12
One Year Survival Probability From the Start of Sildenafil Treatment.
The survival probability of all participants up to 1-year post start of Sildenafil treatment; for participants who were randomized to Sildenafil, this was the week 52 from randomization, and for participants who were originally randomized to Placebo group, this was the Week 64 from Baseline (Week 52 from Week 12, when the first dose of Sildenafil was administered to these participants). Those participants who discontinued from the study prior to 1 year after start of sildenafil were considered as censored at the time of discontinuation and those who discontinued from the study post 1-year after start of sildenafil were considered as censored at the time of 1-year post start of sildenafil.
Time frame: One year from the time of starting sildenafil
One Year Survival From the Start of Sildenafil Treatment.
The survival status of all participants who discontinued from the study, including those participants who discontinued during the double-blind phase, was to be assessed at one year post their Week 12 visit/ End of treatment visit.
Time frame: One year from the time of starting sildenafil
This study was conducted at 29 active centers in 10 countries (10 centers in Germany, 5 centers in the United States of America \[USA\], 3 centers in France, 2 centers in Australia, Czech Republic, Italy, and Israel, and 1 center in Greece, Taiwan and United Kingdom \[UK\])
| Milestone | Placebo | Sildenafil |
|---|---|---|
| Started | 53 | 50 |
| Completed | 48 | 43 |
| Not completed | 5 | 7 |
| Withdrew: Reason unspecified | 0 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Unrelated adverse event | 1 | 0 |
| Withdrew: Related and unrelated adverse event | 1 | 0 |
| Withdrew: Related adverse event | 2 | 2 |
| Milestone | Placebo | Sildenafil |
|---|---|---|
| Started | 48 | 43 |
| Completed | 39 | 31 |
| Not completed | 9 | 12 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Reason unspecified | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Lack of efficacy | 3 | 1 |
| Withdrew: Adverse event | 5 | 5 |
| Withdrew: Protocol violation | 0 | 1 |
6MWT is the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety.
| Meters | Placebo | Sildenafil |
|---|---|---|
| Change from baseline at Week 12 (n=46,44) | 17.42 ± 57.270 | 14.08 ± 63.679 |
| Change from baseline at Week 12 LOCF (n=53,49) | 14.08 ± 57.557 | 13.62 ± 60.950 |
WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity) to Class IV (can not perform a physical activity without any symptoms, dyspnea at rest). Improvement=reduction in functional class; deterioration = increase in functional class, no change = no change in functional class.
| Participants | Placebo | Sildenafil |
|---|---|---|
| Worsened 2 Classes | 0 | 0 |
| Worsened 1 Class | 1 | 0 |
| No Change | 45 | 39 |
| Improved 1 Class | 7 | 10 |
| Improved 2 Classes | 0 | 0 |
| Discontinued | 0 | 0 |
| Died | 0 | 1 |
| Missing | 0 | 0 |
No survival analysis was carried out for the study due to very few events of clinical worsening. Hence, we present a summary of clinical worsening events instead. Events of clinical worsening were categorized as (A). Death, (B). Heart/lung transplantation, (C). Hospitalization due to pulmonary arterial hypertension (PAH), and (D). Clinical deterioration of PAH requiring additional therapy.
| Participants | Placebo | Sildenafil |
|---|---|---|
| None | 51 | 47 |
| (A) | 0 | 1 |
| (B) | 0 | 0 |
| (C) | 2 | 2 |
| (D) | 0 | 0 |
Borg dyspnea scale is a 10-point scale where following scores stands for severity of dyspnea: 0 (no breathlessness at all); 0.5 (very very slight \[just noticeable\]); 1. (very slight); 2. (slight breathlessness); 3. (moderate); 4 (some what severe); 5 (severe breathlessness); 7 (very severe breathlessness); 9 (very very severe \[almost maximum\]); and 10 (maximum).
| Units on a scale | Placebo | Sildenafil |
|---|---|---|
| Change from Baseline at Week 12 (n=46,43) | 0.16 ± 1.637 | -0.73 ± 1.656 |
| Change from Baseline at Week 12 LOCF (n=53,49) | 0.24 ± 1.709 | -0.62 ± 1.583 |
The survival probability of all participants up to 1-year post start of Sildenafil treatment; for participants who were randomized to Sildenafil, this was the week 52 from randomization, and for participants who were originally randomized to Placebo group, this was the Week 64 from Baseline (Week 52 from Week 12, when the first dose of Sildenafil was administered to these participants). Those participants who discontinued from the study prior to 1 year after start of sildenafil were considered as censored at the time of discontinuation and those who discontinued from the study post 1-year after start of sildenafil were considered as censored at the time of 1-year post start of sildenafil.
| Probability of death | Placebo | Sildenafil |
|---|---|---|
| One Year Survival Probability From the Start of Sildenafil Treatment. | 0.042 (0.013 to 0.127) | 0.040 (0.013 to 0.124) |
The survival status of all participants who discontinued from the study, including those participants who discontinued during the double-blind phase, was to be assessed at one year post their Week 12 visit/ End of treatment visit.
| Participants who died | Placebo | Sildenafil |
|---|---|---|
| One Year Survival From the Start of Sildenafil Treatment. | 2 | 2 |
Collected over From the time that the participant provides informed consent through and including 28 calendar days after the last administration of the investigational product. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 23/53 (43.4%) | 38/53 (71.7%) |
| Sildenafil | — | 22/50 (44%) | 33/50 (66%) |
| Event | Placebo | Sildenafil |
|---|---|---|
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 6/53 | 2/50 |
| Right ventricular failureCardiac disorders | 1/53 | 3/50 |
| BronchopneumoniaInfections and infestations | 1/53 | 2/50 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/53 | 2/50 |
| AnaemiaBlood and lymphatic system disorders | 2/53 | 1/50 |
| Abdominal painGastrointestinal disorders | 2/53 | 0/50 |
| ErysipelasInfections and infestations | 2/53 | 0/50 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/53 | 0/50 |
| PneumoniaInfections and infestations | 2/53 | 0/50 |
| Acute coronary syndromeCardiac disorders | 0/53 | 1/50 |
| Event | Placebo | Sildenafil |
|---|---|---|
| Oedema peripheralGeneral disorders | 8/53 | 7/50 |
| NasopharyngitisInfections and infestations | 8/53 | 5/50 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 8/53 | 3/50 |
| DiarrhoeaGastrointestinal disorders | 5/53 | 7/50 |
| HeadacheNervous system disorders | 7/53 | 7/50 |
| VertigoEar and labyrinth disorders | 2/53 | 5/50 |
| BronchitisInfections and infestations | 5/53 | 5/50 |
| FlushingVascular disorders | 4/53 | 5/50 |
| PalpitationsCardiac disorders | 3/53 | 5/50 |
| NauseaGastrointestinal disorders | 5/53 | 1/50 |
| Age, Continuous(Years) | Placebo | Sildenafil | Total |
|---|---|---|---|
| Mean | 56.9 ± 14.14 | 55.2 ± 15.10 | 56.0 ± 14.57 |
| Sex: Female, Male(Participants) | Placebo | Sildenafil | Total |
|---|---|---|---|
| Female | 41 | 37 | 78 |
| Male | 12 | 13 | 25 |
| Six Minute Walk Test (6MWT)(Meters) | Placebo | Sildenafil | Total |
|---|---|---|---|
| Mean | 350.38 ± 87.587 | 354.44 ± 73.121 | 352.35 ± 80.520 |
| Mean Pulmonary Artery Pressure (mPAP)(Millimeter(mm) of mercury(Hg)) | Placebo | Sildenafil | Total |
|---|---|---|---|
| Mean | 44.9 ± 13.33 | 46.9 ± 12.47 | 45.8 ± 12.89 |
| World Health Organization Functional Class in Participants with Pulmonary Arterial Hypertension(Participants) | Placebo | Sildenafil | Total |
|---|---|---|---|
| Class I | 0 | 0 | 0 |
| Class II | 15 | 20 | 35 |
| Class III | 38 | 29 | 67 |
| Class IV | 0 | 1 | 1 |
The record gives a start of Sep 2006, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pulmonary Arterial Hypertension →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →